title: Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.
abstract: Ranolazine (RS-43285) has been shown to possess significant anti-ischaemic properties in a canine model of reversible myocardial ischaemia. The clinical efficacy of this new agent was assessed by a single blind, placebo controlled study of 14 patients with chronic stable angina. A 2 week placebo phase was followed by therapy with 30 mg and 60 mg of ranolazine tid for 2 weeks each. Graded, symptom limited treadmill exercise tests were performed at the end of each phase, 1.5 h (AM) and 7 h (PM) after the morning dose. An additional exercise test 1.5 h after the first dose of 30 mg was included to assess the acute dose response. In the AM study, the mean exercise time increased from 6.9 min (placebo) to 7.8 min after the first dose of 30 mg and to 8.2 min and 8.5 min respectively at the end of 30 mg and 60 mg phases. In the PM study, exercise time improved from 6.5 min (placebo) to 8.2 min and 7.8 min respectively at the end of 30 mg and 60 mg phases. The time to onset of angina showed a similar improvement. No significant changes were observed in the resting and peak exercise heart rates and blood pressure. This preliminary study suggests that ranolazine may significantly prolong exercise time in patients with stable coronary artery disease without altering heart rates and blood pressure.
authors.affiliation: Department of Cardiology, Northwick Park Hospital and Clinical Research Centre, Harrow, Middlesex, England.
authors.forename: D
authors.initials: D
authors.lastname: Jain
authors.forename: P
authors.initials: P
authors.lastname: Dasgupta
authors.forename: L O
authors.initials: LO
authors.lastname: Hughes
authors.forename: A
authors.initials: A
authors.lastname: Lahiri
authors.forename: E B
authors.initials: EB
authors.lastname: Raftery
mesh_terms: D000083:Acetanilides; D000787:Angina Pectoris / Q000188:drug therapy*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D004562:Electrocardiography; D005080:Exercise Test; D006339:Heart Rate / Q000187:drug effects; D005996:Nitroglycerin / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000069458:Ranolazine; D016037:Single-Blind Method
chemical_list: D000083:Acetanilides; D010879:Piperazines; D000069458:Ranolazine; D005996:Nitroglycerin